Skip to content

Inhaled Salbutamol in Elective Caesarean Section

Inhaled Salbutamol in Elective Caesarean Section

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01978418
Acronym
SAISTY
Enrollment
62
Registered
2013-11-07
Start date
2013-11-30
Completion date
2015-12-31
Last updated
2014-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cesarean Section, Postnatal Pulmonary Adaptation

Keywords

Lung fluid, Postnatal adaptation, Salbutamol, Albuterol, Epithelial Sodium Channel

Brief summary

The lungs of the fetus are filled with fluid and it is essential that fetal lung fluid is cleared at birth. This process is mediated through the activation of airway epithelial sodium channels (ENaC). In animals, ENaC is considered crucial for postnatal pulmonary adaptation. In humans, postnatal ENaC expression is dependent on gestational age and its activity, measured as nasal potential difference, correlates with lung compliance. Therefore, in the human newborn infant ENaC may be important for physiologic postnatal adaptation. The activity of ENaC is increased by beta-agonists, such as salbutamol. We hypothesize that low pulmonary expression or activity of ENaC in the perinatal period causes delayed clearance of lung fluid and thereby contributes to the risk for development of transient tachypnea of the newborn (TTN) in term infants born by Caesarean section (CS).

Detailed description

We hypothesize that low pulmonary expression or activity of ENaC in the perinatal period causes delayed clearance of lung fluid and thereby contributes to the risk for development of transient tachypnea of the newborn (TTN) in term infants born by Caesarean section (CS). The aim of this study is to evaluate whether the respiratory status, measured by a transthoracic ultrasound method and lung compliance, of newborns infants born by CS can be improved by inhaled salbutamol at 30-60 minutes of age. 62 infants will be included and randomized to receive salbutamol or placebo-inhalations in a double-blind manner.

Interventions

DRUGsalbutamol

Medication given once as a dose of 4 puffs at 30-60 minutes of age

DRUGPlacebo

Placebo given once as a dose of four puffs at 30-60 minutes of age

Sponsors

Sture Andersson
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
No minimum to 1 Hours
Healthy volunteers
Yes

Inclusion criteria

* healthy singleton pregnancy * Cesarean section at 37 + 0 to 41 + 6 gestational weeks

Exclusion criteria

* clinically significant congenital malformations * birth weight \< 2000 grams * intubation * 200 bp for more than 5 min * relevant medication of the mother, e.g. albetol, beta-agonists (e.g. salbutamol, salmeterol), corticosteroids * the suspicion of/confirmed pneumothorax or infection

Design outcomes

Primary

MeasureTime frameDescription
To evaluate whether lung ultrasound at 30-60 minutes of birth is improved at 3-6 hours of birth6 hoursTo evaluate whether the respiratory status measured by a transthoracic ultrasound method of newborn infants born by CS can be improved by inhaled salbutamol at 30-60 minutes of age.

Secondary

MeasureTime frameDescription
To evaluate whether lung compliance measured at 3-6 hours is improved by inhaled salbutamol at 30-60 minutes of age6 hoursTo evaluate whether lung compliance of newborn infants born by CS can be improved by inhaled salbutamol at 30-60 minutes of age.
Decrease in respiratory rate at 3-6 hours of age6 hoursTo see whether respiratory rate is decreased in infants receiving salbutamol at 30-60 minutes of age
To see whether there is a correlation between airway ENaC expression measured at 30-60 minutes of age and consequent lung fluid content at 3-6 hours of age6 hours
Whether cord blood cortisol concentrations correlate with expression of ENaC and further, with decrease in lung fluid content at 3-6 hours of age6 hours of agewhether cord blood cortisol concentrations correlate with expression of ENaC and further, with decrease in lung fluid content at 3-6 hours of age

Countries

Finland

Contacts

Primary ContactCecilia Janér, MD
cecilia.janer@helsinki.fi+35894711
Backup ContactOtto M Helve, MD, PhD
otto.helve@helsinki.fi+358505824426

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026